Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Prognostic and predictive value of circulating DNA for hepatic arterial infusion of chemotherapy for patients with colorectal cancer liver metastases

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Methylation and ovarian cancer: Can DNA methylation be of diagnostic use?

    Research output: Contribution to journalReviewpeer-review

  1. Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Perspective: targeting VEGF-A and YKL-40 in glioblastoma - matter matters

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Hepatic arterial infusion (HAI) of chemotherapy is an experimental treatment option for patients with colorectal cancer liver metastases (CRCLM). The current study aimed to investigate the predictive and prognostic value of cell free DNA (cfDNA) in patients with CRCLM receiving HAI with oxaliplatin and systemic capecitabine. Plasma samples from 62 patients were investigated who were included into a single arm phase II study investigating HAI treatment for patients with CRCLM. The clinical outcome of the trial has been presented previously. In brief, treatment consisted of intrahepatic infusion of oxaliplatin 100 mg/m2 every second week with concomitant oral capecitabine 3,500 mg/m2 every second week for up to 12 cycles. Blood samples were drawn at baseline and follow-up and plasma was analyzed for cell free DNA using a direct fluorescent assay. The baseline level of plasma cfDNA was 0.92 ng/µl (95% CI 0.84-1.00). Patients with a baseline value of cfDNA above the 75th quartile had a median overall survival of 2.4 years (95% CI 0.7-2.8), compared with 3.9 years (95% CI 2.8-5.9) for patients below the 75th quartile (P=0.02). The baseline level of cfDNA was significantly lower (0.91 ng/µl, 95% CI 0.76-0.98) in patients who achieved an objective response compared to non-responders (1.79 ng/µl; 95% CI 0.99-2.57; P=0.02). The current study demonstrated a possible prognostic and predictive value of cfDNA for patients with CRCLM undergoing HAI with oxaliplatin and concomitant capecitabine.

Original languageEnglish
Article number77
JournalMolecular and Clinical Oncology
Volume13
Issue number6
Pages (from-to)1-6
Number of pages6
ISSN2049-9450
DOIs
Publication statusPublished - Dec 2020

Bibliographical note

Publisher Copyright:
© 2020, Spandidos Publications. All rights reserved.

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

    Research areas

  • Circulating free DNA, Fluorescence, Intrahepatic chemotherapy, Liver metastases, Oxaliplatin

ID: 61900612